{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T23:56:44Z","timestamp":1740182204878,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The traditional Chinese medicine (TCM) formula 01 for nasopharyngeal carcinoma (NPC01) is used in the management of head and neck cancers (HNCs), but whether NPC01 has an impact on the HR-QOL of patients with HNCs is unknown.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a retrospective study of patients with HNCs who were treated between January 2019 and January 2020 at the Head &amp; Neck Cancer Center of Tianjin Medical University Cancer Institute &amp; Hospital. The patients were grouped according to whether they received NPC01 or not (controls). All patients routinely completed the EORTC QLQ-C30 and QLQ-H&amp;N35 modules before and after 3\u2009months of systemic treatment. Health economics were collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patients who received NPC01 were older than the controls (48.6\u2009\u00b1\u200911.4 vs. 43.4\u2009\u00b1\u20098.8\u2009years, <jats:italic>P<\/jats:italic>\u2009=\u20090.004). All other characteristics were comparable between the two groups (all <jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). In EORTC QLQ-C30, physical functioning (<jats:italic>P<\/jats:italic>\u2009=\u20090.03), fatigue (<jats:italic>P<\/jats:italic>\u2009=\u20090.04), pain (<jats:italic>P<\/jats:italic>\u2009=\u20090.02), appetite loss (<jats:italic>P<\/jats:italic>\u2009=\u20090.02), and constipation (<jats:italic>P<\/jats:italic>\u2009=\u20090.01) scores were improved more in the NPC01 group than in controls. In EORTC H&amp;N35, the scores for pain (<jats:italic>P<\/jats:italic>\u2009=\u20090.02), swallowing (<jats:italic>P<\/jats:italic>\u2009=\u20090.01), and dry mouth (<jats:italic>P<\/jats:italic>\u2009=\u20090.02) were better in the NPC01 group than in controls. The NPC01 cost was 38.94 RMB\/patient compared with 12.81 RMB\/patient for regular follow-up, but considering insurance coverage, the financial burden was not higher.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results suggest that NPC01 improves HNCs-related symptoms and HR-QOL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12906-022-03699-7","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T17:02:39Z","timestamp":1660150959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Traditional Chinese medicine formula 01 for nasopharyngeal carcinoma (NPC01) for head &amp; neck cancer and health-related quality of life: a retrospective study"],"prefix":"10.1186","volume":"22","author":[{"given":"Li","family":"Yanwei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"He","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Xudong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3828-9754","authenticated-orcid":false,"given":"Pan","family":"Zhanyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"3699_CR1","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","volume":"371","author":"A Argiris","year":"2008","unstructured":"Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695\u2013709.","journal-title":"Lancet"},{"key":"3699_CR2","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(05)66698-6","volume":"365","author":"WI Wei","year":"2005","unstructured":"Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041\u201354.","journal-title":"Lancet"},{"key":"3699_CR3","unstructured":"Pfister DG, Spencer S, Adelstein D, Adkins D, Darlow SD. Head and neck cancers, version 2.2020, nccn clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2020:18(7);873\u201398."},{"key":"3699_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1102\/1470-7330.2010.0008","volume":"10","author":"DW Tshering Vogel","year":"2010","unstructured":"Tshering Vogel DW, Zbaeren P, Thoeny HC. Cancer of the oral cavity and oropharynx. Cancer Imaging. 2010;10:62\u201372.","journal-title":"Cancer Imaging"},{"issue":"3","key":"3699_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3699_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/CMAR.S115761","volume":"9","author":"C Lo Nigro","year":"2017","unstructured":"Lo Nigro C, Denaro N, Merlotti A, Merlano M. Head and neck cancer: improving outcomes with a multidisciplinary approach. Cancer Manag Res. 2017;9:363\u201371.","journal-title":"Cancer Manag Res"},{"key":"3699_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1634\/theoncologist.2009-0289","volume":"15","author":"D Pulte","year":"2010","unstructured":"Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15:994\u20131001.","journal-title":"Oncologist"},{"key":"3699_CR8","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/annonc\/mdp065","volume":"20","author":"BB Ma","year":"2009","unstructured":"Ma BB, Hui EP, Wong SC, Tung SY, Yuen KK, et al. Multicenter phase II study of gemcitabine and oxaliplatin in advanced nasopharyngeal carcinoma--correlation with excision repair cross-complementing-1 polymorphisms. Ann Oncol. 2009;20:1854\u20139.","journal-title":"Ann Oncol"},{"key":"3699_CR9","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/annonc\/mdf200","volume":"13","author":"RK Ngan","year":"2002","unstructured":"Ngan RK, Yiu HH, Lau WH, Yau S, Cheung FY, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. Ann Oncol. 2002;13:1252\u20138.","journal-title":"Ann Oncol"},{"key":"3699_CR10","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1017\/S0022215116000438","volume":"130","author":"SN Rogers","year":"2016","unstructured":"Rogers SN, Semple C, Babb M, Humphris G. Quality of life considerations in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016;130:S49\u201352.","journal-title":"J Laryngol Otol"},{"key":"3699_CR11","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.oraloncology.2012.03.025","volume":"48","author":"B Ojo","year":"2012","unstructured":"Ojo B, Genden EM, Teng MS, Milbury K, Misiukiewicz KJ, et al. A systematic review of head and neck cancer quality of life assessment instruments. Oral Oncol. 2012;48:923\u201337.","journal-title":"Oral Oncol"},{"key":"3699_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.oraloncology.2007.06.015","volume":"44","author":"B Scott","year":"2008","unstructured":"Scott B, Butterworth C, Lowe D, Rogers SN. Factors associated with restricted mouth opening and its relationship to health-related quality of life in patients attending a maxillofacial oncology clinic. Oral Oncol. 2008;44:430\u20138.","journal-title":"Oral Oncol"},{"key":"3699_CR13","doi-asserted-by":"publisher","first-page":"5291517","DOI":"10.1155\/2018\/5291517","volume":"2018","author":"L Yanwei","year":"2018","unstructured":"Yanwei L, Yinli Y, Pan Z. Traditional herbal formula NPC01 exerts Antiangiogenic effects through inhibiting the PI3K\/Akt\/mTOR signaling pathway in nasopharyngeal carcinoma cells. Evid Based Complement Alternat Med. 2018;2018:5291517.","journal-title":"Evid Based Complement Alternat Med"},{"key":"3699_CR14","first-page":"39","volume":"16","author":"M Nagasawa","year":"1981","unstructured":"Nagasawa M. [consideration for the relation between a book of prescriptions of Chinese traditional medicine \"he ji ju fang\" and pharmacopoeia] (Jpn). Yakushigaku Zasshi. 1981;16:39\u201343.","journal-title":"Yakushigaku Zasshi"},{"key":"3699_CR15","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jep.2016.11.022","volume":"195","author":"A Balap","year":"2017","unstructured":"Balap A, Lohidasan S, Sinnathambi A, Mahadik K. Herb-drug interaction of Andrographis paniculata (Nees) extract and andrographolide on pharmacokinetic and pharmacodynamic of naproxen in rats. J Ethnopharmacol. 2017;195:214\u201321.","journal-title":"J Ethnopharmacol"},{"key":"3699_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/17425255.2017.1251903","volume":"13","author":"D Tang","year":"2017","unstructured":"Tang D, Chen K, Huang L, Li J. Pharmacokinetic properties and drug interactions of apigenin, a natural flavone. Expert Opin Drug Metab Toxicol. 2017;13:323\u201330.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3699_CR17","first-page":"540","volume":"19","author":"CG Mao","year":"2014","unstructured":"Mao CG, Tao ZZ, Wan LJ, Han JB, Chen Z, et al. The efficacy of traditional Chinese medicine as an adjunctive therapy in nasopharyngeal carcinoma: a systematic review and meta-analysis. J BUON. 2014;19:540\u20138.","journal-title":"J BUON"},{"key":"3699_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1534735411403308","volume":"11","author":"CR Chien","year":"2012","unstructured":"Chien CR, Su SY, Cohen L, Lin HW, Lee RT, et al. Use of Chinese medicine among survivors of nasopharyngeal carcinoma in Taiwan: a population-based study. Integr Cancer Ther. 2012;11:221\u201331.","journal-title":"Integr Cancer Ther"},{"key":"3699_CR19","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","volume":"38 Suppl 4","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A, Group EQoL, Quality of Life U. Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2002;38 Suppl 4:S125\u201333.","journal-title":"Eur J Cancer"},{"key":"3699_CR20","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1200\/JCO.1999.17.3.1008","volume":"17","author":"K Bjordal","year":"1999","unstructured":"Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, et al. Quality of life in head and neck cancer patients: validation of the European Organization for Research and Treatment of Cancer quality of life questionnaire-H&N35. J Clin Oncol. 1999;17:1008\u201319.","journal-title":"J Clin Oncol"},{"key":"3699_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1023\/A:1022070220328","volume":"12","author":"WC Chie","year":"2003","unstructured":"Chie WC, Hong RL, Lai CC, Ting LL, Hsu MM. Quality of life in patients of nasopharyngeal carcinoma: validation of the Taiwan Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35. Qual Life Res. 2003;12:93\u20138.","journal-title":"Qual Life Res"},{"key":"3699_CR22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1054\/bjoc.2000.1576","volume":"84","author":"E Hammerlid","year":"2001","unstructured":"Hammerlid E, Taft C. Health-related quality of life in long-term head and neck cancer survivors: a comparison with general population norms. Br J Cancer. 2001;84:149\u201356.","journal-title":"Br J Cancer"},{"key":"3699_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00005537-200001000-00018","volume":"110","author":"A de Graeff","year":"2000","unstructured":"de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, et al. Long-term quality of life of patients with head and neck cancer. Laryngoscope. 2000;110:98\u2013106.","journal-title":"Laryngoscope"},{"key":"3699_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/00005537-200108000-00022","volume":"111","author":"K Bjordal","year":"2001","unstructured":"Bjordal K, Ahlner-Elmqvist M, Hammerlid E, Boysen M, Evensen JF, et al. A prospective study of quality of life in head and neck cancer patients. Part II: Longitudinal data. Laryngoscope. 2001;111:1440\u201352.","journal-title":"Laryngoscope"},{"key":"3699_CR25","first-page":"CD012316","volume":"8","author":"AP Carvalho","year":"2016","unstructured":"Carvalho AP, McNeely ML, Vital FM. Interventions for preventing and treating trismus in patients with head and neck cancer. Cochrane Database Syst Rev. 2016;8:CD012316.","journal-title":"Cochrane Database Syst Rev"},{"key":"3699_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.oraloncology.2015.05.001","volume":"51","author":"A Scherpenhuizen","year":"2015","unstructured":"Scherpenhuizen A, van Waes AM, Janssen LM, Van Cann EM, Stegeman I. The effect of exercise therapy in head and neck cancer patients in the treatment of radiotherapy-induced trismus: a systematic review. Oral Oncol. 2015;51:745\u201350.","journal-title":"Oral Oncol"},{"key":"3699_CR27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1046\/j.1365-2753.2001.00298.x","volume":"7","author":"B Middel","year":"2001","unstructured":"Middel B, Stewart R, Bouma J, van Sonderen E, van den Heuvel WJ. How to validate clinically important change in health-related functional status. Is the magnitude of the effect size consistently related to magnitude of change as indicated by a global question rating? J Eval Clin Pract. 2001;7:399\u2013410.","journal-title":"J Eval Clin Pract"},{"key":"3699_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0360-3016(01)01512-7","volume":"50","author":"A Eisbruch","year":"2001","unstructured":"Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;50:695\u2013704.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3699_CR29","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.ijrobp.2006.11.012","volume":"67","author":"P Graff","year":"2007","unstructured":"Graff P, Lapeyre M, Desandes E, Ortholan C, Bensadoun RJ, et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1309\u201317.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-022-03699-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-022-03699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T17:02:51Z","timestamp":1660150971000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-022-03699-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3699"],"URL":"https:\/\/doi.org\/10.1186\/s12906-022-03699-7","relation":{},"ISSN":["2662-7671"],"issn-type":[{"type":"electronic","value":"2662-7671"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Tianjin Medical University Cancer Institute & Hospital. The need for informed consent was waived by the committee. This data set has been anonymised in order to protect the personal data of those that took part in the study. No animal experiments were performed during the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Individual patient data and images are not presented in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}